for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

42.33EUR

Change

-0.17(-0.40%)

Volume

4,219,432

Today's Range

41.51

 - 

42.42

52 Week Range

41.51

 - 

78.34

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Bayer Submits Supplemental New Drug Application To FDA

Oct 14 (Reuters) - BAYER AG <BAYGn.DE>::BAYER SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR INTRAUTERINE DEVICE (IUD) MIRENA® (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 52 MG.BAYER AG - APPLICATION SEEKS TO EXTEND DURATION OF USE UP TO SEVEN YEARS FOR MIRENA.

Bayer's Phase 3 Study Chronos-3 In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma Meets Primary Endpoint

Oct 14 (Reuters) - Bayer AG <BAYGn.DE>::COMBINATION OF COPANLISIB AND RITUXIMAB SIGNIFICANTLY PROLONGED PROGRESSION-FREE SURVIVAL OF PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA.PHASE III STUDY CHRONOS-3 IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA (INHL) WHO HAVE RECEIVED ONE OR MORE LINES OF PRIOR TREATMENT MEETS PRIMARY ENDPOINT.SAFETY AND TOLERABILITY OBSERVED IN TRIAL WERE GENERALLY CONSISTENT WITH PREVIOUSLY PUBLISHED DATA ON INDIVIDUAL COMPONENTS OF COMBINATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED.COPANLISIB IS ALREADY APPROVED IN U.S. UNDER ACCELERATED APPROVAL BASED ON OVERALL RESPONSE RATE (ORR) OF 104 ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL) BASED ON PHASE II CHRONOS-1 STUDY.

EU Gives Bayer Green Light For Full Launch Of Xtendflex Soybeans in 2021

Sept 28 (Reuters) - Bayer AG <BAYGn.DE>::BAYER'S XTENDFLEX SOYBEANS GAIN FINAL KEY REGULATORY APPROVAL.EUROPEAN COMMISSION'S GREEN LIGHT ENABLES A FULL LAUNCH IN 2021.WITH THIS APPROVAL IN HAND, BAYER CAN NOW LOOK FORWARD TO A FULL LAUNCH IN UNITED STATES AND CANADA IN 2021 AND EXPECTS TO BE IN A STRONG POSITION TO SUPPLY 20 MILLION U.S. SOY ACRES WHEN SELLING SEASON ARRIVES.WE EXPECT LAUNCH OF XTENDFLEX TO MATCH LAUNCH SCALE OF ROUNDUP READY 2 XTEND SOYBEANS.

Spie Wins Contract From Bayer For IoT-based Showroom

Sept 24 (Reuters) - SPIE SA <SPIE.PA>::INSTALLS A SHOWROOM FOR BAYER AG BASED ON AN IOT PLATFORM.SHOWROOM WILL SERVE AS PROTOTYPE FOR FUTURE BAYER BUREAUS.

Bayer: Good Tolerability Of Nubeqa In Men With High-Risk nmCRPC

Sept 22 (Reuters) - BAYER AG <BAYGn.DE>::NEW ANALYSIS CONFIRMS GOOD TOLERABILITY OF NUBEQA (DAROLUTAMID) AT RECOMMENDED DOSES IN MEN WITH HIGH-RISK NMCRPC.

Bayer Collaborates With Recursion To Strengthen Digital Drug Discovery

Sept 9 (Reuters) - BAYER AG <BAYGn.DE>::COLLABORATES WITH RECURSION TO STRENGTHEN DIGITAL DRUG DISCOVERY AND ADVANCE NEW THERAPIES FOR FIBROTIC DISEASES.BAYER AND US-BASED RECURSION PHARMACEUTICALS, INC., A DIGITAL BIOLOGY COMPANY INDUSTRIALIZING DRUG DISCOVERY, HAVE ENTERED INTO A STRATEGIC COLLABORATION AGREEMENT.IN ADDITION, LEAPS BY BAYER, THE IMPACT INVESTMENT ARM OF BAYER AG, IS LEADING RECURSION’S SERIES D FINANCING WITH AN INVESTMENT OF USD 50 MILLION..RECURSION'S DRUG DISCOVERY PLATFORM COMBINES HIGHLY AUTOMATED, WET LAB BIOLOGY EXPERIMENTS AS BASE FOR ITERATIVE LEARNING THROUGH ITS COMPUTATIONAL TOOLS.PURPOSE-BUILT DRUG-DISCOVERY PLATFORM IS BASED ON A PROPRIETARY LIBRARY OF OVER HALF A BILLION IMAGES OF HUMAN CELLS FROM MORE THAN 33 MILLION EXPERIMENTS CONDUCTED IN-HOUSE AT RECURSION AND COUPLED WITH ADVANCED DATA ANALYTICS BASED ON MACHINE LEARNING.TO DATE, RECURSION HAS ON-BOARDED OVER 750 CELLULAR DISEASE MODELS TO BROADLY INTERROGATE DIVERSE THERAPEUTIC AREAS.UNDER THE TERMS OF THE AGREEMENT, THE PARTIES MAY INITIATE MORE THAN TEN PROGRAMS WITH POSSIBLE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS OF MORE THAN USD 100 MILLION PER PROGRAM PLUS ROYALTIES ON FUTURE SALES.IN ADDITION TO THE USD 50 MILLION EQUITY INVESTMENT, RECURSION WILL RECEIVE AN UPFRONT PAYMENT OF USD 30 MILLION.

Bayer Completes Acquisition Of Kandy Therapeutics

Sept 9 (Reuters) - Bayer AG <BAYGn.DE>::BAYER COMPLETES ACQUISITION OF UK-BASED BIOTECH COMPANY KANDY THERAPEUTICS LTD..ANTITRUST CLEARANCE CLOSING OF ACQUISITION HAS NOW BEEN ACHIEVED.

Bayer Says Phase 4 Study Met Its Main Goal In PAH Patients Who Transitioned To Adempas

Sept 7 (Reuters) - Bayer AG <BAYGn.DE>::BAYER PHASE IV STUDY MET ITS PRIMARY ENDPOINT IN PAH PATIENTS WHO HAD TRANSITIONED TO ADEMPAS (RIOCIGUAT) AFTER INSUFFICIENT RESPONSE TO PDE5 INHIBITORS.BAYER - OUTCOMES FROM RANDOMIZED, CONTROLLED, OPEN-LABEL REPLACE STUDY INCLUDED RESULTS FROM 226 PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION.BAYER - MOST COMMON ADVERSE EVENTS INSTUDY WERE GENERALLY CONSISTENT WITH THOSE SEEN IN PIVOTAL PATENT STUDY.

China Isotope & Radiation Corp Says Xofigo Developed By Bayer Officially Approved By NMPA

Aug 31 (Reuters) - China Isotope & Radiation Corp <1763.HK>::ON 27 AUG, XOFIGO DEVELOPED BY BAYER OFFICIALLY APPROVED BY NMPA.

Bayer And Northpond Ventures Lead Financing Round For Triumvira Immunologics

Aug 27 (Reuters) - BAYER AG <BAYGn.DE>::BAYER AND NORTHPOND VENTURES LEAD USD 55 MILLION SERIES A FINANCING ROUND FOR TRIUMVIRA IMMUNOLOGICS.PIPELINE INCLUDES FOUR THERAPEUTIC CANDIDATES FOR BOTH AUTOLOGOUS AND ALLOGENEIC T-CELL IMMUNO THERAPIES FOR TREATMENT OF LIQUID AND SOLID TUMORS.LEAPS BY BAYER AND NORTHPOND VENTURES CO-LEAD THE INVESTMENT TO SUPPORT DEVELOPMENT OF NEXT-GENERATION IMMUNO ONCOLOGY TREATMENTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up